Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
Research ArticleClinical Investigations

Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors

Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin and Rodney J. Hicks
Journal of Nuclear Medicine April 2015, 56 (4) 505-511; DOI: https://doi.org/10.2967/jnumed.114.145581
Delphine Denoyer
1Molecular Imaging and Targeted Therapeutics, Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
2Centre for Cellular and Molecular Biology, Deakin University, Burwood, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavel Lobachevsky
3Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Price Jackson
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mick Thompson
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga A. Martin
3Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney J. Hicks
1Molecular Imaging and Targeted Therapeutics, Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 56 no. 4 505-511
DOI 
https://doi.org/10.2967/jnumed.114.145581
PubMed 
25722453

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication July 14, 2014
  • Accepted for publication December 8, 2014
  • Published online April 1, 2015.

Article Versions

  • previous version (February 26, 2015 - 05:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Delphine Denoyer1,2,
  2. Pavel Lobachevsky3,4,
  3. Price Jackson5,
  4. Mick Thompson5,
  5. Olga A. Martin*,3–5 and
  6. Rodney J. Hicks*,1,4,5
  1. 1Molecular Imaging and Targeted Therapeutics, Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
  2. 2Centre for Cellular and Molecular Biology, Deakin University, Burwood, Australia
  3. 3Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
  4. 4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
  5. 5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  1. For correspondence or reprints contact either of the following:
  2. Olga A. Martin, Peter MacCallum Cancer Centre, 12 St. Andrew’s Place, East Melbourne, VIC 3002, Australia. E-mail: olga.martin{at}petermac.org
  3. Delphine Denoyer, Centre for Cellular and Molecular Biology, Deakin University, 221 Burwood Hwy., Burwood, VIC 3125, Australia. E-mail: d.denoyer{at}deakin.edu.au
View Full Text

Cited By...

  • 23 Citations
  • Google Scholar

Article usage

Article usage: February 2015 to February 2021

AbstractFullPdf
Feb 201582010
Mar 2015206054
Apr 2015122743121
May 20153251338
Jun 2015187827
Jul 2015129826
Aug 201597820
Sep 2015123712
Oct 2015851017
Nov 2015642424
Dec 2015662726
Jan 2016802618
Feb 2016842331
Mar 2016562340
Apr 2016611227
May 2016452821
Jun 2016531918
Jul 2016281718
Aug 2016501425
Sep 2016381918
Oct 2016612245
Nov 2016451118
Dec 2016251616
Jan 2017551816
Feb 2017372515
Mar 2017351913
Apr 201720129
May 2017211820
Jun 201715518
Jul 2017191310
Aug 201791116
Sep 201717816
Oct 201735913
Nov 201728289
Dec 2017172310
Jan 2018604016
Feb 2018232213
Mar 201819268
Apr 201824219
May 201832288
Jun 20189143
Jul 20189162
Aug 20187102
Sep 2018202213
Oct 201820306
Nov 201815299
Dec 201812339
Jan 2019252813
Feb 201913376
Mar 2019134321
Apr 2019123122
May 2019111617
Jun 201910611
Jul 2019132317
Aug 201991316
Sep 201911513
Oct 2019141014
Nov 201914613
Dec 2019171312
Jan 20203289
Feb 2020221214
Mar 202036619
Apr 2020132026
May 202091120
Jun 202018612
Jul 20201146
Aug 202014718
Sep 20207612
Oct 202016512
Nov 202013614
Dec 2020131222
Jan 202122120
Feb 202192221
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 56 (4)
Journal of Nuclear Medicine
Vol. 56, Issue 4
April 1, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin, Rodney J. Hicks
Journal of Nuclear Medicine Apr 2015, 56 (4) 505-511; DOI: 10.2967/jnumed.114.145581

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin, Rodney J. Hicks
Journal of Nuclear Medicine Apr 2015, 56 (4) 505-511; DOI: 10.2967/jnumed.114.145581
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • γ-H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
  • Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
  • Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
  • The Relevance of Dosimetry in Precision Medicine
  • Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
  • Localized Synchrotron Irradiation of Mouse Skin Induces Persistent Systemic Genotoxic and Immune Responses
  • Radiotherapy for Non-Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues
  • Myeloid neoplasms after chemotherapy and PRRT: myth and reality
  • DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy
  • Radiopeptides for Imaging and Therapy: A Radiant Future
  • {gamma}-H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
  • Google Scholar

More in this TOC Section

  • Nuclear Imaging for Classic Fever of Unknown Origin: Meta-Analysis
  • A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition
  • Utility of Equilibrium Radionuclide Angiogram–Derived Measures of Dyssynchrony to Predict Outcomes in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy
Show more Clinical Investigations

Similar Articles

Keywords

  • 177Lu-octreotate
  • PRRT
  • normal tissue toxicity
  • DNA damage
  • γ-H2AX
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire